Phillip Minar, MD, MS

Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's Disease. Irie, K; Minar, P; Reifenberg, J; Boyle, BM; Noe, JD; Hyams, JS; Mizuno, T. Clinical Pharmacokinetics. 2025; 64:1669-1679.

Magnetic resonance imaging for suspected perianal Crohn's disease in children: a multi-reader agreement study. Debnath, P; Acord, MR; Anton, CG; Courtier, J; El-Ali, AM; Forbes-Amrhein, MM; Gee, MS; Greer, ML C; Guillerman, RP; Kocaoglu, M; Zhang, B; Frischer, JS; Minar, P; Dillman, JR. European Radiology. 2025; 35:5856-5863.

Acute pancreatitis gut dysbiosis persists at 1-year follow-up and is associated with clinical outcomes. Dike, CR; Duan, Q; Ahmed, F; Denson, LA; Haslam, D; Minar, P; Ollberding, NJ; Papachristou, GI; Setchell, KD R; Thompson, T; Vitale, DS; Zhao, X; Abu-El-Haija, M. Journal of Pediatric Gastroenterology and Nutrition. 2025; 81:690-698.

Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease: A Nationwide Survey of Anti-TNF Therapy Practices, Attitudes, and Barriers. Colman, RJ; Dotson, JL; Mock, M; Sandberg, K; Saeed, S; Margolis, P; Dhaliwal, J; Strople, J; Russell, G; Rountree, C; Ebach, DR; Adler, J; Wali, P; Yeung, KJ A. Crohn's and Colitis 360. 2025; 7:otaf050.

Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease. Moses, J; Adler, J; Saeed, SA; Firestine, AM; Galanko, JA; Ammoury, RF; Bass, DM; Bass, JA; Bastidas, M; Benkov, KJ; Wohl, DA; Zikry, M; Boyle, BM; Kappelman, MD. Inflammatory Bowel Diseases. 2025; 31:1841-1850.

Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease. Dillman, JR; Tkach, JA; Fletcher, JG; Bruining, DH; Lu, A; Kugathasan, S; Alazraki, AL; Knight-Scott, J; Stidham, RW; Adler, J; Anton, CG; Imbus, RA; Dudley, JA; Denson, LA. Inflammatory Bowel Diseases. 2025; 31:1380-1391.

HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. Adler, J; Galanko, JA; Ammoury, R; Benkov, KJ; Bousvaros, A; Boyle, B; Cabrera, JM; Chun, KY; Dorsey, J; Ebach, DR; Strople, JA; Sullivan, JS; Wali, PD; Kappelman, MD. The American Journal of Gastroenterology (Elsevier). 2025; 120:1076-1086.

Tu2094: COHORT FOR PEDIATRIC TRANSLATIONAL AND CLINICAL RESEARCH IN IBD (CAPTURE IBD): INITIAL ENROLLMENT OF A DIVERSE AND ADVANCED THERAPY-EXPOSED PROSPECTIVE COHORT. Sifuentes-Dominguez, L; Bauman, LE; Subedi, S; Chevalier, RL; Niklinska-Schirtz, BJ; Hoffenberg, EJ; De Zoeten, E; Shapiro, J; Goyal, A; Albenberg, L; Sauer, C; Huang, JS; Kahn, SA; Rosen, MJ. Gastroenterology. 2025; 169:s-1607.

36: LONGITUDINAL MICROBIAL SIGNATURES PREDICT DRUG CONCENTRATIONS, IMMUNOGENICITY, AND ENDOSCOPIC HEALING IN PEDIATRIC PATIENTS WITH CROHN’S DISEASE TREATED WITH ANTI-TNF THERAPY. Colman, RJ; Lopez-Rivera, J; Pinto, Y; Hyams, JS; Boyle, BM; Noe, JD; Minar, PP; Rosen, MJ. Gastroenterology. 2025; 169:s-13-s-14.

Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab. Bartel, C; Minar, P. Alimentary Pharmacology and Therapeutics. 2025; 61:1063-1064.